Rilpivirine: Drug profile of a second-generation non-nucleoside reverse transcriptase HIV-inhibitor

Expert Review of Anti-Infective Therapy

Volumn 12, Issue 1, 2014, Pages 13-29

  Ripamonti, Diego ^a   Bombana, Enrico ^a   Rizzi, Marco ^a  

^a Azienda Ospedaliera Papa Giovanni XXIII   (Italy)

Author keywords

antivirals; highly active antiretroviral therapy; HIV infection; HIV therapy; non nucleoside reverse transcriptase inhibitor; rilpivirine; TMC278

Indexed keywords

ALANINE AMINOTRANSFERASE; ATORVASTATIN; DARUNAVIR; EFAVIRENZ; EMTRICITABINE PLUS RILPIVIRINE PLUS TENOFOVIR DISOPROXIL; ETHINYLESTRADIOL PLUS NORETHISTERONE; FAMOTIDINE; KETOCONAZOLE; LONG ACTING DRUG; LOPINAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MACROGOL 400; METHADONE; NANOPARTICLE; OMEPRAZOLE; PLACEBO; PROTEINASE INHIBITOR; RIFABUTIN; RIFAMPICIN; RILPIVIRINE; RITONAVIR; SILDENAFIL; TENOFOVIR; TENOFOVIR DISOPROXIL; TRIACYLGLYCEROL; VIRUS RNA;

ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CD4 LYMPHOCYTE COUNT; CENTRAL NERVOUS SYSTEM DISEASE; CROSS RESISTANCE; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FOOD DRUG INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MORTALITY; NIGHTMARE; NONHUMAN; PHARMACODYNAMICS; PHENOTYPE; QT PROLONGATION; SINGLE DRUG DOSE; TABLET FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; TUBERCULOSIS; VIRUS RESISTANCE;

ANTI-HIV AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG INTERACTIONS; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; NITRILES; PYRIMIDINES;

EID: 84893065832     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2014.863708     Document Type: Article

References (69)

1. Mocroft A, Ledergerber B, Katlama C et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 362(9377), 22-29 (2003).
2. Hirsch MS, Gunthard HF, Schapiro JM et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: recommendations of an international AIDS Society-USA Panel. Clin. Infect. Dis. 47(2), 266-285 (2008).
3. Paterson DL, Swindells S, Mohr J et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann. Intern. Med. 133(1), 21-30 (2000).
4. Janssen PA, Lewi PJ, Arnold E et al. In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2- cyanoethenyl]- 2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile (R278474, rilpivirine). J. Med. Chem. 48(6), 1901-1909 (2005).
5. Das K, Bauman JD, Clark AD Jr et al. High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations. Proc. Natl Acad. Sci. USA 105(5), 1466-1471 (2008).
6. Van Herrewege Y, Vanham G, Michiels J et al. A series of diaryltriazines and diarylpyrimidines are highly potent nonnucleoside reverse transcriptase inhibitors with possible applications as microbicides. Antimicrob. Agents Chemother. 48(10), 3684-3689 (2004).
7. Mordant C, Schmitt B, Pasquier E et al. Synthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains. Eur. J. Med. Chem. 42(5), 567-579 (2007).
8. Katlama C, Haubrich R, Lalezari J et al. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS 23(17), 2289-2300 (2009).
9. Desmidt M, Willems B, Dom P et al. Absence of a teratogenic potential from a novel next-generation NNRTI, TMC278. Program and Abstracts of the 12th European AIDS Conference. Cologne, Germany, 11-14 November 2009 (Abstract PE7.1/4).
10. Basavapathruni A, Vingerhoets J, de Be'thune MP et al. Modulation of human immunodeficiency virus type 1 synergistic inhibition by reverse transcriptase mutations. Biochemistry 45(23), 7334-7340 (2006).
11. Azijn H, Tirry I, Vingerhoets J et al. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob. Agents Chemother. 54(2), 718-727 (2010).
12. Frenkel YV, Gallicchio E, Das K et al. Molecular dynamics study of non-nucleoside reverse transcriptase inhibitor 4-[[4-[[4-[(E)- 2-cyanoethenyl]-2,6-dimethylphenyl]amino]- 2-pyrimidinyl]amino]benzonitrile (TMC278/rilpivirine) aggregates: correlation between amphiphilic properties of the drug and oral bioavailability. J. Med. Chem. 52(19), 5896-5905 (2009).
13. Tambuyzer L, Azijn H, Rimsky LT et al. Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors. Antivir. Ther. 14(1), 103-109 (2009).
14. Rimsky L, Vingerhoets J, Van Eygen V et al. Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis. J. Acquir. Immune. Defic. Syndr. 59(1), 39-46 (2012).
15. De Bethune MP, Andries K, Azijn H et al. TMC278, a new potent NNRTI, with an increased barrier to resistance and favorable pharmacokinetic profile. Program and Abstracts of the 12th Conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts, USA, 22-25 February 2005 (Abstract 556).
16. Lachaud-Durand S, Mamidi NRVS, Cuyckens F et al. Absoption, metabolism and excretion of TMC278, an NNRTI, after a single oral dose of 150 mg in healthy male volunteers. 12th European AIDS Conference. Cologne, Germany, 11-14 November 2009 (Abstract PE7.1/3).
17. Hoetelmans RMW, Kestens D, Stevens M et al. Effect of food and multiple-dose pharmacokinetic of TMC278 as an oral tablet formulation. Program and Abstracts of the 5th International Workshop on Clinical Pharmacology of HIV 2005. Quebec, Canada (Abstract P6.9).
18. Crauwels HM, van Heeswijk RP, Buelens A, Stevens M, Boven K, Hoetelmans RM. Impact of food and different meal types on the pharmacokinetics of rilpivirine. J. Clin. Pharmacol. 53(8), 834-840 (2013)
19. Custodio JM, Yin X, Hepner M, Ling J, Cheng A, Kearney BP, Ramanathan S. Effect of food on rilpivirine/emtricitabine/tenofovir disoproxil fumarate, an antiretroviral single-tablet regimen for the treatment of HIV infection. J. Clin. Pharmacol. doi:10.1002/jcph.208 (2013) (Epub ahead of print).
20. Goebel F, Yakovlev A, Pozniak A et al. Short-term antiviral activity of TMC278 - a novel NNRTI - in treatment-naive HIV-1-infected subjects. AIDS 20(13), 1721-1726 (2006).
21. Van Gyseghem E, Pendela M, Baert L et al. Powder for reconstitution of the anti-HIV-1 drug TMC278 - Formulation development, stability and animal studies. Eur. J. Pharm. Biopharm. 70(3), 853-860 (2008).
22. Crauwels HM, van Heeswijk RPG, McNeeley DF et al. Relative biovailability of a concept paediatric formulation of TMC278, an investigational NNRTI. Program and Abstracts of the 18th International AIDS Conference. Vienna, Austria, 2010 (Abstract THPE0158).
23. Draper BH, Morroni C, Hoffman M et al. Depot medroxyprogesterone versus norethisterone oenanthate for long-acting progestogenic contraception. Cochrane Database Syst. Rev. 19(3), CD005214 (2006).
24. Love RC, Conley RJ. Long-acting risperidone injection. Am. J. Health Syst. Pharm. 61(17), 1792-1800 (2004).
25. Destache CJ, Belgum T, Christensen K et al. Combination antiretroviral drugs in PLGA nanoparticle for HIV-1. BMC Infect. Dis. 9, 198 (2009).
26. Destache CJ, Belgum T, Goede M et al. Antiretroviral release from poly(DL-lactideco- glycolide) nanoparticles in mice. J. Antimicrob. Chemother. 65(10), 2183-2187 (2010).
27. van't Klooster G, Hoeben E, Borghys H et al. Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation. Antimicrob. Agents Chemother. 54(5), 2042-2050 (2010).
28. Else L, Jackson A, Tjia J et al. Pharmacokinetics of long-acting rilpivirine in plasma, genital tract and rectum of HIV-negative females and males administered a single 600 mg dose. 13th International Workshop on Clinical Pharmacology of HIV Therapy. Barcelona, Spain, 16-18 April 2012 (Abstract O-12).
29. Spreen W, Williams P, Margolis D et al. First study of repeat dose co-administration of GSK1265744 and TMC278 long-acting parenteral nanosuspensions: pharmacokinetics, safety, and tolerability in healthy adults. 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Kuala Lumpur, Malaysia, 30 June-3 July (2013).
30. Vanveggel S, Buelens A, Crauwels HM et al. TMC278 25 mg qd has no effect on corrected QT interval in a study in HIV-negative volunteers. Program and Abstracts of the 12th European AIDS Conference. Cologne, Germany 2009 (Abstract PE7.1/2)
31. Hoetelmans RMW, van Heeswijk RPG, Kestens D et al. The pharmacokinetic (PK) interaction between TMC278 an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) and lopinavir/ritonavir (LOP/r) in healthy volunteers. Program and Abstracts of the 10th European AIDS. Dublin, Ireland, 17-20 November 2005 (Abstract PE4.3/1).
32. van Heeswijk RPG, Hoetelmans RMW, Kestens D et al. The pharmacokinetic (PK) interaction between TMC278, a next generation non-nucleoside reverse transcriptase inhibitor (NNRTI), and once daily darunavir/ritonavir (DRV/r) in HIV-negative volunteers. Program and Abstracts of the 47th ICAAC. Chicago, USA, September 2007 (Abstract H-1042).
33. Hoetelmans RMW, Kestens D, Stevens M et al. The pharmacokinetic (PK) interaction between the novel next generation Non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC278 and tenofovir diproxil fumarate (TDF) in healthy volunteers. Program and Abstracts of the 3rd IAS Conference on Pathogenesis, Treatment and Prevention. 2005 (Abstract P 2.11).
34. van Heeswijk R, Hoetelmans R, Kestens D et al. The pharmacokinetic interaction between ketoconazole and TMC278, an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), in healthy HIV-negative subjects. Program and Abstracts of the 16th International Conference on AIDS. 2006 (Abstract TUPE0087).
35. Scholler-Gyure M, Debroye C, Vyncke V et al. The effects of CYP3A4 modulation on the pharmacokinetics of TMC278, a non-nucleoside reverse transcriptase inhibitor (NNRTI). Program and Abstracts of the 7th International Workshop on Clinical Pharmacology of HIV Therapy. 2006 (Abstract P4.3/04).
36. Crauwels HM, van Heeswijk RPG, Kestens D et al. The pharmacokinetic (PK) interaction between rifabutin and TMC278, an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI). Program and Abstracts of the 17th International Conference on AIDS. 2008 (Abstract TUPE0080).
37. Crauwels HM, van Heeswijk RPG, Kestens D et al. The pharmacokinetic interaction between omeprazole and TMC278, an investigational NNRTI. Program and Abstracts of the 9th International Congress on Drug Therapy in HIV Infection. Glasgow, Scotland, 9-13 November 2008 (Poster 239).
38. van Heeswijk R, Hoetelmans R, Kestens D et al. The pharmacokinetic (PK) interaction between famotidine and TMC278, a next generation non-nucleoside reverse transcriptase inhibitor (NNRTI), in HIV-negative volunteers. Program and Abstracts of the 4th IAS Conference on Pathogenesis, Treatment and Prevention. Sydney, Australia, 2007 (Abstract TUPDB01).
39. Crauwels HM, van Heeswijk RPG, and Vandevoorde A et al. Pharmacokinetic interaction study between TMC278, a next-generation NNRTI, and methadone. Program and Abstracts of the 18th International AIDS Conference. Vienna, Austria, 2010 (Abstract WEPE0089).
40. Crauwels HM, van Heeswijk RPG, and Stevens T et al. TMC278, a next generation of nucleoside reverse transcriptase inhibitor, does not alter the pharmacokinetics of sildenafil. Program and Abstracts of the 10th International Workshop on Clinical Pharmacology of HIV Therapy. (Abstract P22).
41. Crauwels HM, van Heeswijk RPG, Cornelis L et al. Pharmacokinetic interaction study between TMC278, an NNRTI, and the contraceptive norethindrone plus ethynilestradiol. Program and Abstracts of the 12th European AIDS Conference. Cologne, Germany, 2009 (Abstract PE4.3/3).
42. van Heeswijk RPG, Hoetelmans RMW, Aharchi F et al. The pharmacokinetic (PK) interaction between atorvastatin (AVS) TMC278, a next generation non-nucleoside reverse transcriptase inhibitor (NNRTI) in HIV-negative volunteers. Program and Abstracts of the 11th European AIDS Conference. Cologne, Germany, 2007 (Abstract 45).
43. Arastéh K, Rieger A, Yeni P et al. Short-term randomized proof-of-principle trial of TMC278 in patients with HIV type-1 who have previously failed antiretroviral therapy. Antivir. her. 14(5), 713-722 (2009).
44. Pozniak AL, Morales-Ramirez J, Katabira E et al. Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week results of a phase IIb randomized trial. AIDS 24(1), 55-65 (2010).
45. Molina JM, Cahn P, Grinsztejn B, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind activecontrolled trial. Lancet 378(9787), 238-246 (2011).
46. Cohen CJ, Andrade-Villanueva J, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet 378(9787), 229-237 (2011).
47. Cohen CJ, Molina JM, Cassetti I et al. Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials. AIDS 27(6), 939-950 (2013).
48. Rimsky L, Van Eygen V, Hoogstoel A et al. 96-week resistance analyses of rilpivirine in treatment-naive, HIV-1-infected adults from the ECHO and THRIVE Phase III trials. Antivir. Ther. doi:10.3851/IMP2636 (2013) (Epub ahead of print).
49. Nelson M, Amaya G, Clumeck N et al. Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials. J. Antimicrob. Chemother. 67(8), 2020-2028 (2012).
50. Crauwels HM, van Schaick E, van Heeswijk RPG et al. Effect of intrinsic and extrinsic factors on the pharmacokinetics of TMC278 in antiretroviral-nave, HIV-1-infected patients in ECHO and THRIVE. 10th International Congress on Drug Therapy in HIV Infection. Glasgow, 7-11 November 2010 (Poster 186).
51. Palella F, Tebas P, Gazzard B et al. SPIRIT study: switching to emtricitabine/rilpivirine/tenofovir (FTC/RPV/TDF) single-tablet regimen (STR) from a ritonavir-boosted protease inhibitor and two nucleoside reverse transcriptase inhibitors (NRTIs) maintains HIV suppression and improves serum lipids in HIV-positive subjects. 19th International AIDS Conference. Washington, USA, 22-27 July 2012 (Abstract TUAB0104).
52. Mills AM, Cohen C, Dejesus E, et al. Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens. HIV Clin. Trials. 14(5), 216-233 (2013).
53. Cohen C, Wohl D, Arribas J et al. STAR study: single tablet regimen emtricitabine/rilpivirine/tenofovir DF is non-inferior to efavirenz/ emtricitabine/tenofovir DF in ART-nave patients. Eleventh International Congress on Drug Therapy in HIV Infection. Glasgow, 2012 (Abstract O425).
54. Anta L, Llibre JM, Poveda E, et al. Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies. AIDS 27(1), 81-85 (2013).
55. Asahchop EL, Wainberg MA, Oliveira M, et al. Distinct resistance patterns to etravirine and rilpivirine in viruses containing nonnucleoside reverse transcriptase inhibitor mutations at baseline. AIDS 27(6), 879-887 (2013).
56. Tambuyzer L, Nijs S, Daems B, Picchio G, Vingerhoets J. Effect of mutations at position E138 in HIV-1 reverse transcriptase on phenotypic susceptibility and virologic response to etravirine. J. Acquir. Immune. Defic. Syndr. 58(1), 18-22 (2011).
57. Zolopa A, Sax PE, DeJesus E et al. A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results. J. Acquir. Immune. Defic. Syndr. 63(1), 96-100 (2013).
58. Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 374(9692), 796-806 (2009).
59. Walmsley S, Antela A, Clumeck N et al. Dolutegravir (DTG; S/GSK1349572) + abacavir/lamivudine once daily statistically superior to tenofovir/ emtricitabine/efavirenz: 48-week results - SINGLE (ING114467). 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 2012 (Abstract H-556b).
60. Reinheimer C, Doerr H, Stu?rmer M. Prevalence of TMC278 (rilpivirine) associated mutations in the Frankfurt Resistance Database. J. Clin. Virol. 53(3), 248-250 (2012).
61. Melikian GL, Rhee SY, Varghese V et al. Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing. J. Antimicrob. Chemother. doi:10.1093/jac/dkt316 (2013) (Epub ahead of print).
62. DeJesus E, Lalezari JP, Osiyemi OO et al. Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults. Antivir. Ther. 15(5), 711-720 (2010).
63. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents U.S. department of health and human services panel on antiretroviral guidelines for adults and adolescents -a working group of the office of AIDS research advisory council (OARAC). www.aidsinfo.nih.gov/ contentfiles/lvguidelines/aa-recommendations.pdf (Accessed November 2013)
64. Guidelines: clinical management and treatment of HIV infected adults in Europe. Nov 2012. www.europeanaidsclinicalsociety. org/index.php?option=com- content &view=article&id=59&Itemid=41 (Accessed November 2013)
65. Johnson VA, Vincent Calvez V, Gunthard HF et al. 2011 Update of the drug resistance mutations in HIV-1. www.matecmichigan.org/A%20Drug% 20Resistance%20Mutations%20in% 20HIV-1%20%202011.pdf
66. Australian public assessment report for rilpivirine. www.tga.gov.au/pdf/ auspar/ausparrilpivirine- 120327.pdf
67. Database of antiretroviral drug interactions. All interactions with RPV. hivinsite.ucsf.edu/insite?page=ar- 00-02¶m=205&post=4
68. All interactions with RPV. Site developed and maintained by The University of Liverpool and eMedFusion. www.hiv-druginteractions.org/ InteractionDetailList.aspx? HIVDrugId=511&Page=NNRTI
69. TMC278-TiDP6-C130: Pharmacokinetics, safety and tolerability of TMC278 in subjects with mildly or moderately impaired hepatic function. www.clinicaltrials.gov/ct2/show/NCT00736905